Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DY 9760

Drug Profile

DY 9760

Alternative Names: DY 9760e

Latest Information Update: 13 May 2008

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Piperazines
  • Mechanism of Action Calmodulin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neurological disorders

Most Recent Events

  • 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
  • 29 Nov 2004 A preclinical study has been added to the Neurological disorders pharmacodynamics section
  • 22 May 2003 A clinical study has been added to the Neurological disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top